国药控股：国药一致前三季度归母净利约9.57亿元，同比减少10.18%

Core Insights - The company reported a total operating revenue of approximately 55.12 billion yuan for the first three quarters of 2025, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was approximately 957 million yuan, down 10.18% year-on-year [1] - The basic earnings per share were 1.72 yuan [1] Distribution Segment - The distribution segment achieved operating revenue of 40.59 billion yuan from January to September 2025, a year-on-year decline of 0.59% [2] - Net profit for the distribution segment was 723 million yuan, down 7.32% year-on-year [2] - Despite ongoing policy and market competition pressures, the company managed to stabilize distribution revenue through continuous optimization of its business structure [2] Retail Segment - The retail segment, represented by "Guoyao Holdings Guoda Pharmacy Co., Ltd.", generated operating revenue of 15.23 billion yuan, a year-on-year decrease of 7.14% [2] - The net profit for the retail segment was 13 million yuan, showing a significant year-on-year increase of 133.91% [2] - The retail segment faced challenges from the market environment and strategic store closures, but improved profitability through optimization of procurement systems and closure of inefficient stores [2]